Study of DP303c Injection in Patients With Advanced Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicentre, phase II study to evaluate the efficacy and safety
of of DP303c injection in patients with HER2-expressing advanced ovarian cancer.